During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...
Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...
Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...
Dearbhla was diagnosed in July 2022 with multiple myeloma, a type of bone marrow cancer that can affect the spine, skull, ...
Stand Up To Cancer® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a ...
Stand Up To Cancer (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to ...
Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...
In a real-world study involving patients with standard-risk, newly-diagnosed multiple myeloma (NDMM), there was no significant ... Study findings were reported in the journal Bone Marrow ...